home / stock / ktta / ktta news

KTTA News and Press, Pasithea Therapeutics Corp. From 11/20/25

Stock Information
Company Name: Pasithea Therapeutics Corp.
Stock Symbol: KTTA
Market: NASDAQ
Website: pasithea.com
Menu
KTTA KTTA Quote KTTA Short KTTA News KTTA Articles KTTA Message Board
Get KTTA Alerts

News, Short Squeeze, Breakout and More Instantly...
KTTA - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

-- Evidence of Monotherapy Activity : Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved s...
KTTA - US Companies Moving the Markets, Morning edition
Thu, Nov 20, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States Autozi Internet Technology (Global) Ltd. (AZI) rose 12.0% to $0.085 on volume of 480,945,530 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 5.1% to $4.13 on volume of 355,767,751 shares Freight Technologies Inc. (FRGT) r...

KTTA - US Companies Moving the Markets, Evening edition
Wed, Nov 19, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Autozi Internet Technology (Global) Ltd. (AZI) rose 14.5% to $0.0869 on volume of 455,993,718 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.7% to $4.145 on volume of 295,215,577 shares Freight Technologies Inc. (FRGT)...

KTTA - Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced activation of a new U...
KTTA - Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced activation of two South Ko...

KTTA - Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” ...

KTTA - Morning Market Recap: Precision Medicine Clears the Path, A&D Soars, and Gaming Gets a Buyback Boost

2025-08-29 10:09:15 ET DENVER, Colo., Aug 29, 2025 ( 247marketnews.com )- A flurry of pivotal developments across diagnostics, biotech, aerospace, pet retail, and mobile gaming set the tone for today’s markets. NeoGenomics (NASDAQ:NEO) secured a major legal victory—...
KTTA - Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of...

KTTA - Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced management will participat...

KTTA - Expected US Company Earnings on Tuesday, August 12th, 2025

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...
Previous 10 Next 10